SC
VRDN icon

SummitTX Capital’s Viridian Therapeutics VRDN Stock Holding History

SummitTX Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,066
Closed -$567K – 1021
2025
Q1 		$567K Buy
+42,066
New +$717K 0.02% 515

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SummitTX Capital's VRDN Position: Q2 2025 in Review

SummitTX Capital sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 42,066 shares — an estimated $567K sold.

SummitTX Capital first reported a position in VRDN in Q1 2025 and held it in 1 quarter. The position peaked at $567K in Q1 2025. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • SummitTX Capital reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SummitTX Capital sold 42,066 Viridian Therapeutics shares in Q2 2025, an estimated $567K.
  • SummitTX Capital first reported a position in Viridian Therapeutics in Q1 2025 and held it in 1 quarter.
  • SummitTX Capital's Viridian Therapeutics position peaked at $567K in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.